Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Phase 3

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Placebo
Drug: Apatinib

First Posted Date: 2015-01-06

Last Posted Date: 2017-02-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 417

Registration Number: NCT02332512

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Placebo
Drug: Apatinib

First Posted Date: 2015-01-01

Last Posted Date: 2024-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT02329860

Locations: 🇨🇳
Jiangsu hengrui medicine CO. LTD, Lianyungang, Jiangsu, China

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Apatinib

First Posted Date: 2012-07-31

Last Posted Date: 2013-12-03

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT01653561

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: apatinib

First Posted Date: 2012-02-13

Last Posted Date: 2015-04-03

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT01531777

Locations: 🇨🇳
Fudan University cancer hospital, Shanghai, Shanghai, China

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Advanced or Metastatic Gastric Cancer

Interventions: Drug: placebo
Drug: apatinib

First Posted Date: 2012-01-19

Last Posted Date: 2016-10-17

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 267

Registration Number: NCT01512745

Locations: 🇨🇳
The 81 Hosiptal of PLA, Nanjing, Jiangsu, China
🇨🇳
Fudan University cancer hospital, Shanghai, Shanghai, China

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Phase 3

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: apatinib
Drug: placebo

First Posted Date: 2011-02-02

Last Posted Date: 2013-12-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 480

Registration Number: NCT01287962

Locations: 🇨🇳
Cancer Center of Sun Yat-Sen University (CCSU), Guangzhou, Guangdong, China

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: placebo
Drug: apatinib

First Posted Date: 2011-01-05

Last Posted Date: 2012-02-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 136

Registration Number: NCT01270386

Locations: 🇨🇳
Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Apatinib

First Posted Date: 2010-09-01

Last Posted Date: 2023-03-03

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 121

Registration Number: NCT01192971

Locations: 🇨🇳
Nanjing Millitary Eighty-one Hosiptal, Nanjing, Jiangsu, China

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Apatinib

First Posted Date: 2010-08-06

Last Posted Date: 2015-09-09

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT01176669

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1

Conditions: Tumor

Interventions: Drug: apatinib

First Posted Date: 2008-03-12

Last Posted Date: 2008-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 18

Registration Number: NCT00633490

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy